EHA 2022 | Long-term results of BELIEVE: luspatercept in adults with transfusion-dependent beta-thalassemia
Ali Taher, MD, PhD, American University of Beirut Medical Center, Beirut, Lebanon, gives an overview of the mechanism of action of luspatercept and discusses the long-term results of the Phase III BELIEVE study (NCT02604433) which evaluated luspatercept in patients with transfusion-dependent beta-thalassemia. After a period of three years, the study reported a benefit for patients treated with luspatercept, with a high number of patients achieving transfusion independence. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Novartis Pharmaceuticals: Consultancy, Research funding; Bristol-Myers Squibb (Celgene): Consultancy, Research funding; Ionis Pharmaceuticals: Consultancy, Research Funding; Vifor: Consultancy, Research Funding; Imara: Consultancy, Research Funding; Agios: Consultancy
